Coronial
NSWother

Inquest into the deaths of James UNICOMBE, Michael POOLE, Grace YATES

Deceased

James Francis Unicomb, Michael Poole, Grace Yates

Coroner

Decision ofState Coroner Jerram

Date of death

2005-12-10, 2008-03-29, 2010-11-30

Finding date

2012-09-27

Cause of death

Three deaths with different primary causes: James Unicomb - acute toxicity due to multiple self-administered drugs; Michael Poole - ruptured berry aneurysm and consequences, bronchopneumonia; Grace Yates - acute bronchopneumonia following hypoxic-ischaemic encephalopathy caused by cardio-respiratory arrest post-ROD treatment

AI-generated summary

Combined inquest into three deaths at Psyche South Clinic involving treatment failures: James Unicomb (22, 2005) from multi-drug overdose after naltrexone implant; Michael Poole (48, 2008) from ruptured aneurysm post-Rapid Opioid Detoxification; Grace Yates (24, 2010) from hypoxic-ischaemic encephalopathy after ROD. All were unsuitable for offered treatments due to contraindications inadequately assessed. James's death not directly implant-related but would have benefited from methadone continuation; Michael's possibly preventable with proper post-discharge medical support and appropriate accommodation; Grace's preventable: proceeded with ROD despite ECG contraindications showing prolonged QTc, then received inadequate post-procedure monitoring. Critical clinical lessons: never use unapproved experimental treatments in vulnerable patients without robust protocols, proper informed consent, and comprehensive pre-treatment assessment documenting contraindications; maintain adequate staffing and continuous monitoring post-procedure; provide structured aftercare with medical supervision; ensure appropriate support on discharge.

AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes. Report an inaccuracy.

Specialties

addiction medicinegeneral practicepsychologyemergency medicineintensive carecardiology

Error types

diagnosticmedicationproceduralcommunicationsystemdelay

Drugs involved

naltrexonenaloxonemethadoneheroinmorphinecodeinediazepambenzodiazepinesmethamphetamine

Clinical conditions

opioid dependencedepressionprolonged qtc intervalsubarachnoid haemorrhageberry aneurysmdissecting aortic aneurysmhypoxic ischaemic encephalopathybronchopneumoniacardio-respiratory arrestacute drug toxicity

Procedures

naltrexone implant insertionrapid opioid detoxificationelectrocardiogramresuscitation attempts

Contributing factors

  • Inadequate pre-treatment medical assessment
  • Patients unsuitable for treatments offered due to contraindications
  • Use of experimental/unapproved pharmacological treatments without Therapeutic Goods Administration approval
  • Failure to provide informed consent; consent forms not explained to patients
  • Lack of discussion of alternative evidence-based treatments such as methadone
  • Grossly inadequate medical staffing and expertise
  • Severely inadequate nursing staffing
  • Inadequate training and supervision of nursing and other staff
  • Inadequate monitoring and observation of patients post-treatment
  • Inadequate records and documentation
  • Absence of clinical protocols and policies
  • Lack of aftercare support and medical follow-up
  • Inappropriate discharge arrangements to unsupported accommodation
  • Clinic not licensed for Rapid Opioid Detoxification when treating Grace
  • ECG showed prolonged QTc interval (relative contraindication to ROD) but treatment proceeded
  • Minimal expense-based operation prioritizing cost over patient care and safety
  • Failure to implement NSW Health Guidelines for Rapid Opioid Detoxification

Coroner's recommendations

  1. Forward findings to Health Care Complaints Commission for consideration of proceedings against Dr D.
  2. Endorse statements and recommendations of Australian National Council on Drugs Position Statement on Naltrexone Sustained Release Preparations (March 2012), including: only pharmacological treatments with Therapeutic Goods Administration approval should be available for routine use; treatments without TGA approval should go through formal registration processes; ongoing use of TGA Special Access Scheme for naltrexone implants is inappropriate; further independent clinical trials needed on safety and efficacy of sustained release naltrexone preparations; full and informed consent must be obtained prior to treatment; TGA and Department of Health & Ageing should resolve ongoing use of Special Access Scheme for naltrexone implants
Full text

Source and disclaimer

This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.

Content may be incomplete, reformatted, or summarised. Some material may have been redacted or restricted by court order or privacy requirements. Always refer to the original court publication for the authoritative record.

Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction — report an inaccuracy here.